Merck & Co Inc (MRK)

62.79
0.08 0.13
NYSE : Health Care
Prev Close 62.71
Open 62.86
Day Low/High 62.42 / 63.12
52 Wk Low/High 47.97 / 64.00
Volume 8.86M
Avg Volume 10.06M
Exchange NYSE
Shares Outstanding 2.77B
Market Cap 174.24B
EPS 1.60
P/E Ratio 34.62
Div & Yield 1.84 (2.90%)

Latest News

Top 10 Dividend Stocks to Buy in September

Top 10 Dividend Stocks to Buy in September

Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.

Intermediate Trade: Merck

Intermediate Trade: Merck

The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.

Cramer: The 'Just You Wait' Crowd Keeps Waiting

Cramer: The 'Just You Wait' Crowd Keeps Waiting

The market continues to defy those players who believe we are seeing the calm before the storm.

Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors

Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors

The FDA approved Merck's Keytruda, a drug to treat metastatic and recurrent cancer.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Initiating a Position in a Biotech Name

Don't be surprised; we view Bristol-Myers as "down, not out."

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

How Will Merck (MRK) Stock React to Potential Medivation Bid?

How Will Merck (MRK) Stock React to Potential Medivation Bid?

Merck (MRK), along with at least four other pharmaceuticals companies, has reportedly shown interest in acquiring Medivation (MDVN).

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Don't Write Off Bristol-Myers After Opdivo Setback

Don't Write Off Bristol-Myers After Opdivo Setback

BMY is unlikely to stay in the low $60s for long.

Results From Merck's Phase 3 Study Evaluating ZEPATIER™ (elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C Receiving Treatment For Opioid Dependence Published In Annals Of Internal Medicine

Results From Merck's Phase 3 Study Evaluating ZEPATIER™ (elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C Receiving Treatment For Opioid Dependence Published In Annals Of Internal Medicine

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR.

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

The Ironic Chess Game of Bristol-Myers

The Ironic Chess Game of Bristol-Myers

The failed trial is among the biggest single blows by a major pharma player.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

Trending Tickers: CHK, MUR, MRO, BMY

Trending Tickers: CHK, MUR, MRO, BMY

Rising crude prices help buoy a host of oil companies Monday.

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.

Health Care Drags Stocks Away From Records

Health Care Drags Stocks Away From Records

Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.

Merck Gets a Big Shot in the Arm

Merck Gets a Big Shot in the Arm

One day does not make a trend, but one day can certainly reinforce an existing trend.

Merck (MRK) Stock Upgraded at Credit Suisse

Merck (MRK) Stock Upgraded at Credit Suisse

Merck (MRK) stock was upgraded to 'outperform' at Credit Suisse after Bristol-Myers's (BMY) non-small cell lung cancer treatment missed its primary endpoint.

4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid

4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Morning Movers: MFRM, DAL, AMZN, BMY

Morning Movers: MFRM, DAL, AMZN, BMY

Mattress Firm soars on takeover bid, while Delta's worldwide computer issues are causing the stock to drop.

Analysts' Actions -- Bristol-Myers, Merck, JPMorgan, Weyerhaeuser and More

Analysts' Actions -- Bristol-Myers, Merck, JPMorgan, Weyerhaeuser and More

Here are Monday's top research calls, including downgrades for Bristol-Myers Squibb, JPMorgan and Weyerhaeuser, and an upgrade for Merck.

What Next for Bristol-Myers and Merck?

What Next for Bristol-Myers and Merck?

BMY's loss definitely looks like MRK's gain.

Takeaways, Observations and Tesla: Best of Kass

Takeaways, Observations and Tesla: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us why self-confident, glib and dogmatic is no way to go through life, son.